Mirae Asset Global Investments Co. Ltd. Lowers Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Mirae Asset Global Investments Co. Ltd. decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 21.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,428 shares of the biopharmaceutical company's stock after selling 2,764 shares during the quarter. Mirae Asset Global Investments Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $2,867,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ALNY. Allspring Global Investments Holdings LLC raised its stake in Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Alnylam Pharmaceuticals during the second quarter worth about $26,000. Altitude Crest Partners Inc. acquired a new position in Alnylam Pharmaceuticals during the first quarter worth about $30,000. Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter worth about $51,000. Finally, Meeder Asset Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 1,237.5% during the second quarter. Meeder Asset Management Inc. now owns 321 shares of the biopharmaceutical company's stock worth $78,000 after purchasing an additional 297 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Bank of America boosted their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an "equal weight" rating in a report on Friday, July 12th. Canaccord Genuity Group boosted their price target on Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a "buy" rating in a report on Friday, August 2nd. Wells Fargo & Company boosted their price target on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an "equal weight" rating in a report on Friday, August 2nd. Finally, Raymond James boosted their price target on Alnylam Pharmaceuticals from $242.00 to $275.00 and gave the stock an "outperform" rating in a report on Friday, August 2nd. Six investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $290.86.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Dennis A. Ausiello sold 20,250 shares of the company's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the transaction, the director now directly owns 136 shares of the company's stock, valued at $35,632. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, CEO Yvonne Greenstreet sold 15,148 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $270.00, for a total value of $4,089,960.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company's stock, valued at approximately $19,829,070. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Dennis A. Ausiello sold 20,250 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now directly owns 136 shares of the company's stock, valued at $35,632. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,398 shares of company stock valued at $13,595,460 over the last ninety days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of Alnylam Pharmaceuticals stock traded down $3.20 on Wednesday, reaching $281.49. 976,404 shares of the company's stock were exchanged, compared to its average volume of 867,922. The company has a market capitalization of $35.61 billion, a P/E ratio of -105.03 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm's 50-day moving average is $274.75 and its two-hundred day moving average is $224.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period in the previous year, the company earned ($2.21) earnings per share. Alnylam Pharmaceuticals's revenue for the quarter was up 107.0% compared to the same quarter last year. On average, analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.